• Fevzi Altuntas, Naim Ata, Tugce Nur Yigenoglu, Semih Bascı, Mehmet Sinan Dal, Serdal Korkmaz, Sinem Namdaroglu, Abdulkadir Basturk, Tuba Hacıbekiroglu, Mehmet Hilmi Dogu, İlhami Berber, Kursat Dal, Kerem Kınık, İbrahim Haznedaroglu, Fatma Meriç Yılmaz, İsa Kılıç, Sinan Demircioğlu, Alper Yosunkaya, Mehmet Ali Erkurt, Burhan Turgut, Murat Caglayan, and Osman Celik.
• University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey; Ankara Yıldırım Beyazıt University, School of Medicine, Department of Hematology, Ankara, Turkey. Electronic address: faltuntas@hotmail.com.
• Transfus Apher Sci. 2021 Feb 1; 60 (1): 102955.

IntroductionPassive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19.MethodThe data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively.ResultsDuration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (≤5 days, 6-10 days, 11-15 days) (p=0.001).ConclusionCP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients.Copyright © 2020 Elsevier Ltd. All rights reserved.

20 keywords...

hide…